gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.


erythropoietin, EPO
Top mentioned proteins: CAN, HAD, AGE, V1a, erythropoietin receptor
Papers using erythropoietin antibodies
Interferon-gamma mediates suppression of erythropoiesis but not reduced red cell survival following CpG-ODN administration in vivo.
Vij Neeraj, In PLoS ONE, 2005
... Human Erythropoietin (rhuEPO) was purchased from GenScript Corporation (Piscataway, NJ) ...
Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy
Fima Eyal et al., In International Journal of Cell Biology, 1994
... Rabbit antisera against EPO were purchased from Fitzgerald (Concord, Mass, USA) ...
Papers on erythropoietin
Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis.
Hodson et al., Aberdeen, United Kingdom. In Cochrane Database Syst Rev, Feb 2016
BACKGROUND: Treatment with recombinant human erythropoietin (rHuEPO) in dialysis patients has been shown to be highly effective in terms of correcting anaemia and improving quality of life.
Hepcidin and Iron Metabolism in Pregnancy: Correlation with Smoking and Birth Weight and Length.
Ołtarzewski et al., Warsaw, Poland. In Biol Trace Elem Res, Feb 2016
The smoking mothers had significantly lower concentrations of serum hepcidin (p < 0.001), iron (p < 0.001), and hemoglobin (p < 0.05), but higher erythropoietin (p < 0.05) levels compared with non-smoking pregnant women.
Evolving insights into the synergy between erythropoietin and thrombopoietin and the bipotent Erythroid/Megakaryocytic progenitor cell.
Kaushansky et al., Seattle, United States. In Exp Hematol, Feb 2016
UNASSIGNED: Although the synergy between erythropoietin and thrombopoietin was previously pointed out , the clonal demonstration of a human bipotent Erythroid/Megakaryocytic progenitor (MEP) was first published in ExpHem (April 1996) and later in the same year by Debili et al in Blood.
Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis.
Stüve et al., Dallas, United States. In Neurotherapeutics, Feb 2016
In this review, we discuss various therapies under study in phase II or III trials, including antioxidants (idebenone); tyrosine kinase inhibitors (masitinib); sphingosine receptor modulators (siponimod); monoclonal antibodies (anti-leucine-rich repeat and immunoglobulin-like domain containing neurite outgrowth inhibitor receptor-interacting protein-1, natalizumab, ocrelizumab, intrathecal rituximab); hematopoetic stem cell therapy; statins and other possible neuroprotective agents (amiloride, riluzole, fluoxetine, oxcarbazepine); lithium; phosphodiesterase inhibitors (ibudilast); hormone-based therapies (adrenocorticotrophic hormone and erythropoietin); T-cell receptor peptide vaccine (NeuroVax); autologous T-cell immunotherapy (Tcelna); MIS416 (a microparticulate immune response modifier); dopamine antagonists (domperidone); and nutritional supplements, including lipoic acid, biotin, and sunphenon epigallocatechin-3-gallate (green tea extract).
The effects of cinacalcet treatment on bone mineral metabolism, anemia parameters, left ventricular mass index and parathyroid gland volume in hemodialysis patients with severe secondary hyperparathyroidism.
Ozelsancak et al., Adana, Turkey. In Saudi J Kidney Dis Transpl, Jan 2016
The initial and one-year results of adjusted serum calcium (Ca +2 ), phosphate (P), Ca × P product, PTH, hemoglobin (Hb) and ferritin levels, transferrin saturation index (TSAT), median weekly erythropoietin (EPO) dose, LVMI, and parathyroid volume by parathyroid ultrasonography were determined.
Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial.
ANZICS Clinical Trials Group et al., Melbourne, Australia. In Lancet, Jan 2016
METHODS: Erythropoietin in Traumatic Brain Injury (EPO-TBI) was a double-blind, placebo-controlled trial undertaken in 29 centres (all university-affiliated teaching hospitals) in seven countries (Australia, New Zealand, France, Germany, Finland, Ireland, and Saudi Arabia).
Regeneration in the nervous system with erythropoietin.
Maiese, Newark, United States. In Front Biosci, Dec 2015
Erythropoietin (EPO) offers an exciting and novel therapeutic strategy to address both acute and chronic neurodegenerative disorders.
Circulating growth arrest-specific protein 6 levels are associated with erythropoietin resistance in hemodialysis patients.
Chou et al., Taipei, Taiwan. In Springerplus, Dec 2015
Growth arrest-specific protein 6 (Gas6) works synergistically with erythropoietin (EPO) to increase the proliferation and maturation of erythroblasts.
Erythropoietin Stimulates Tumor Growth via EphB4.
Sood et al., Houston, United States. In Cancer Cell, Dec 2015
While recombinant human erythropoietin (rhEpo) has been widely used to treat anemia in cancer patients, concerns about its adverse effects on patient survival have emerged.
PPAR-α and glucocorticoid receptor synergize to promote erythroid progenitor self-renewal.
Lodish et al., Cambridge, United States. In Nature, Jul 2015
Many acute and chronic anaemias, including haemolysis, sepsis and genetic bone marrow failure diseases such as Diamond-Blackfan anaemia, are not treatable with erythropoietin (Epo), because the colony-forming unit erythroid progenitors (CFU-Es) that respond to Epo are either too few in number or are not sensitive enough to Epo to maintain sufficient red blood cell production.
Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
Keck et al., United States. In J Clin Oncol, Jun 2015
PATIENTS AND METHODS: Priming with intravenous iron and erythropoietin occurred to increase hemoglobin (Hb) pretransplantation.
Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands.
Garcia et al., Stanford, United States. In Cell, Apr 2015
We utilized diabodies (DA) as surrogate ligands in a prototypical dimeric receptor-ligand system, the cytokine Erythropoietin (EPO) and its receptor (EpoR), to dimerize EpoR ectodomains in non-native architectures.
Transplantation of erythropoietin gene-transfected umbilical cord mesenchymal stem cells as a treatment for limb ischemia in rats.
Song et al., Zhengzhou, China. In Genet Mol Res, 2014
The aim of this study was to investigate the mechanisms of erythropoietin (EPO)-transfected umbilical cord mesenchymal stem cells (UC-MSCs) in the treatment of rats with ischemic limb and provide a theoretical basis for optimization of UC-MSC transplantation.
Effect of neural stem cell transplantation combined with erythropoietin injection on axon regeneration in adult rats with transected spinal cord injury.
Xiao et al., Hohhot, China. In Genet Mol Res, 2014
We investigated the effect of neural stem cells (NSC) and erythropoietin (EPO) on axon regeneration in adult rats with transected spinal cord injury, and provided an experimental basis for clinical treatment.
The Role of the Multiple Hormonal Dysregulation in the Onset of "Anemia of Aging": Focus on Testosterone, IGF-1, and Thyroid Hormones.
Ceda et al., Parma, Italy. In Int J Endocrinol, 2014
Experimental studies suggest that anabolic hormones such as testosterone, IGF-1, and thyroid hormones are able to increase erythroid mass, erythropoietin synthesis, and iron bioavailability, underlining a potential role of multiple hormonal changes in the anemia of aging.
Functional conservation of erythropoietin signaling in zebrafish.
Zon et al., Boston, United States. In Blood, 2007
characterization of zebrafish epo and epor demonstrates the conservation of an ancient program that ensures proper red blood cell numbers during normal homeostasis and under hypoxic conditions
share on facebooktweetadd +1mail to friends